Source
Rare Disease Advisor
Eplontersen constitutes a promising improvement in the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR), according to a new literature review published in Health Science Reports.
“Future research is needed on long-term safety, early diagnosis, personalized treatments, and combination therapies,” the researchers said. “This drug emphasizes the importance of continued research for optimal patient care and outcomes.”
To summarize the mechanism of action, safety, and efficacy of eplontersen as well as ongoing clinical trials, a team of researchers led by Omniat Amir Hussin, MBBS, from Al-Manhal University in Khartoum, Sudan, conducted a systematic review of literature, analyzing 6 studies.
News Url